"AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that IMBRUVICA® (ibrutinib) was awarded the prestigious Prix Galien 2015 Award for Best Pharmaceutical Agent. IMBRUVICA won this distinction out of 24 category nominees, all of which were deemed innovative in the field of medicine and were approved by the U.S. Food and Drug Administration (FDA) within the past five years. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.":
prnewswire.com/news-release...
Encouragingly, there are hopefully even better CLL drugs on the way, but we'll need some brave clinical trial volunteers to prove that's the case..
Neil
Chemo-Free Treatment Best Option for CLL Patients Under 70
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
Imbruvica cost exact figures
